Westpac Banking Corp increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 89.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 293,866 shares of the biopharmaceutical company’s stock after purchasing an additional 138,537 shares […]
Reuter James Wealth Management LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 15.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,604 shares of the biopharmaceutical company’s stock after selling 3,195 shares during the quarter. Gilead […]
Bogart Wealth LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 46.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,847 shares of the biopharmaceutical company’s stock after selling 60,279 shares during the quarter. Bogart Wealth LLC’s holdings […]
Los Angeles Capital Management LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,285,237 shares of the biopharmaceutical company’s stock after acquiring an additional 155,507 shares during the […]
Legacy Financial Advisors Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 18.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,547 shares of the biopharmaceutical company’s stock after acquiring an additional 1,651 shares during the period. […]